Health TrialsbyHealthPanel

Cannabis Abstinence and Neurocognitive Assessment in Adolescence

ConditionsCannabis DependenceHarmful UseCognitive Assessment
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age15-18
SponsorUniversity Hospital Pilsen

About this trial

Cannabis Abstinence and Neurocognitive Assessment in Adolescence

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Adolescents aged 15-18 years with a diagnosis of cannabis dependence or harmful cannabis use.

Disqualifiers

psychiatric comorbidity - Dual diagnosis, including psychotic disorders, mood disorders, severe organic brain damage, or autism spectrum disorder, with the exception of compensated and stabilized anxiety disorder. Psychopharmacological treatment is permitted, except for antipsychotics prescribed for psychosis.

somatic comorbidity - Severe endocrine disorders such as diabetes mellitus, thyroid dysfunction, or severe cardiovascular disease.

Violation of abstinence between the first and second neuropsychological assessments, as well as severe decompensation of mental state requiring modification of established psychopharmacological treatment.

Trial population

Adolescents aged 15-18 years with a diagnosis of cannabis dependence or harmful cannabis use.

Trial design

Design model

Case-only

Time perspective

Prospective

Treatments tested in this trial

  • Neurocognitive assessment

    Diagnostic test

    Neurocognitive battery: TMT-Trail Making Test Auditory Verbal Learning Test Stroop Test Tower of London (ToL), Shallice version Continuous Performance Test-Identical Pairs Other psychometrics: The level of dependence is quantified using the CAST (Cannabis Abuse Screening Test)

  • Urine toxicological assessment

    Diagnostic test

    Urine toxicological assessment

Treatment groups

29 Participants
are divided into 1 treatment group
Group A: Group 12 interventions

Trial outcomes

Primary outcomes

1

Change in performance TMT-B

Change in performance on the Trail Making Test - Part B (TMT-B) \[Time Frame: after 8 weeks of abstinence from cannabis\]

Time frame
8 weeks

Secondary outcomes

1

Change in performance on AVLT

Change in performance on the Auditory Verbal Learning Test (AVLT) \[Time Frame: after 8 weeks of abstinence\]

Time frame
8 weeks
2

Change in performance on the Stroop Test

Change in performance on the Stroop Test \[Time Frame: after 8 weeks of abstinence\]

Time frame
8 weeks
3

Change in performance on the Tower of London

Change in performance on the Tower of London (Shallice version) \[Time Frame: after 8 weeks of abstinence\]

Time frame
8 weeks
4

Change in performance on CPT-IP

Change in performance on the Continuous Performance Test - Identical Pairs (CPT-IP) \[Time Frame: after 8 weeks of abstinence\]

Time frame
8 weeks

Other outcomes

1

Cannabis Abuse Screening Test versus degree of neurocognitive impairment

Correlation between severity of cannabis dependence (Cannabis Abuse Screening Test, CAST) and degree of neurocognitive impairment \[Time Frame: baseline and after 8 weeks of abstinence\]

Time frame
8 weeks

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

University Hospital Pilsen

Lead sponsor

Source ClinicalTrials.gov
Apply now